The nomogram was then constructed based on TNM staging and the expression levels of ATF2, SLC27A5, and ALOXE3 to quantitatively predict 1-, 3-, and 5-year survival probabilities, providing a reference for clinical decision-making in ESCC patients. This evidence concerns the gene ALOXE3 and esophageal squamous cell carcinoma.